(Reuters) - The diabetes drug, CS-917, failed to significantly lower glycosylated hemoglobin, a measure of glucose load, in patients with type 2 diabetes, the most common form of the disease.
"We are surprised and disappointed by the results we have seen so far in this important Phase 2b clinical trial," Dr. Mark Erion, executive vice president of research and development, said in a statement.
Read more at Reuters.com Hot Stocks News
"We are surprised and disappointed by the results we have seen so far in this important Phase 2b clinical trial," Dr. Mark Erion, executive vice president of research and development, said in a statement.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment